Shineway Pharm (02877) announced that as of September 30, 2024, the unaudited management accounts for the nine months has not been reviewed by the auditor...
According to the Zhitong Finance APP, Shineway Pharm (02877) announced that as of September 30, 2024, the unaudited management accounts for the nine months recorded a total operating income of 2.887 billion yuan, a decrease of 16.9% compared to the same period in 2023. Breakdown: Revenue from injection products decreased by 26.7% to 1.028 billion yuan; revenue from soft capsule products decreased by 19.3% to 0.391 billion yuan; revenue from granule products decreased by 2.2% to 0.457 billion yuan; revenue from traditional chinese medicine formula granule products decreased by 12.0% to 0.824 billion yuan; and revenue from other dosage forms increased by 2.6% to 0.187 billion yuan.
By product type analysis, as of September 30, 2024, injection products, soft capsule products, granule products, and traditional chinese medicine formula granule products accounted for approximately 35.6%, 13.5%, 15.8%, and 28.5% of the group's total operating income, respectively.
